PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Analyst Ratings Changes
PTCT has been the topic of several analyst reports. Credit Suisse Group lifted their target price on PTC Therapeutics to $52.00 in a research report on Friday, July 22nd. Royal Bank of Canada lifted their target price on PTC Therapeutics from $42.00 to $46.00 and gave the company a "sector perform" rating in a research report on Thursday, June 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, PTC Therapeutics has a consensus rating of "Hold" and a consensus price target of $51.75.
PTC Therapeutics Price Performance
NASDAQ:PTCT traded down $2.30 on Tuesday, reaching $51.11. 12,232 shares of the company's stock traded hands, compared to its average volume of 590,686. The company has a quick ratio of 1.59, a current ratio of 1.62 and a debt-to-equity ratio of 679.17. The stock has a 50-day simple moving average of $38.75 and a 200-day simple moving average of $37.95. The firm has a market cap of $3.65 billion, a PE ratio of -6.57 and a beta of 0.64. PTC Therapeutics has a 12 month low of $25.01 and a 12 month high of $54.29.
PTC Therapeutics (NASDAQ:PTCT - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.13) EPS for the quarter, missing analysts' consensus estimates of ($1.66) by ($0.47). The business had revenue of $165.50 million for the quarter, compared to the consensus estimate of $162.53 million. PTC Therapeutics had a negative net margin of 89.89% and a negative return on equity of 10,562.67%. PTC Therapeutics's revenue was up 41.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.68) earnings per share. Equities research analysts forecast that PTC Therapeutics will post -5.62 earnings per share for the current year.